ReviewVaccines2021
Nanomaterial Delivery Systems for mRNA Vaccines.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 269 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
269 citing papers in PubMed.
- Surface charge of LNP and V-ATPase activity of target cell synergize in functional delivery of nucleic acidInternational journal of pharmaceutics: X · 2026Article
- Translating base editors: a decade of progress from the bench to the clinic.Nature reviews. Drug discovery · 2026Review
- Safe and sustainable by design (SSbD) for nanotechnology: scientific foundations, global policy perspectives, and industrial practice.Nano convergence · 2026Review
- An Investigation of Water Vapor Sorption for Improving Reconstitution Pathways of Freeze-Dried Lipid Nanoparticles Stabilized by Trehalose/Mannitol Excipients.AAPS PharmSciTech · 2026Article
- Comprehensive Analytical Characterization of mRNA Influenza Vaccine Under Stress Conditions: Implications for Stability and Quality Control.Pharmaceutical research · 2026Article
- Development of an mRNA vaccine against the OprF ofMicrobiology spectrum · 2026Article
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Membrane environment sets the functional pKBiophysical journal · 2026Article
- Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation.Pharmaceutics · 2026Review
- Plant-derived CTLA-4-targeting miR152 via lipid nanoparticles potentiates doxorubicin efficacy in breast cancer immunochemotherapy.Science China. Life sciences · 2026Article
- Finding the sweet spot between complexation and cytosolic release with different molecular weight branched polyethyleneimine polymers for mRNA delivery.Drug delivery and translational research · 2026Article
- Development of a Lensless Compact Optical System for Ultrasensitive Nanomaterial Detection in Liquid Media via Exploiting Multiple Light Scattering.Nanophotonics (Berlin, Germany) · 2026Article
- Mapping mRNA Localization and Internal Structure in Lipid Nanoparticles through Solid-State Dynamic Nuclear Polarization NMR and Proton Spin-Diffusion Modeling.Small methods · 2026Article
- Development of a microneedle patch for delivery of mRNA-lipid nanoparticles.Drug delivery and translational research · 2026Article
- Analytical Characterization and Stability Assessment of RNA-Based Vaccines.Pharmaceutics · 2026Review
- Next-generation mRNA vaccines: strategies to overcome stability challenges.NPJ vaccines · 2026Article
- Multiscale modeling guided potency assessment of mRNA-lipid nanoparticles.Molecular therapy. Nucleic acids · 2026Article
- Antioxidant lipid nanoparticles enhance mRNA stability for regeneration therapy and gene editing.Nature communications · 2026Article
- Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Efficacy and Safety of Messenger RNA Vaccines.Health science reports · 2026Article
209 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.